PRPH, US74345W2070

ProPhase Labs faces USD 25 million claim: what it means for ProPhase Labs stock

Published on 10/14/2026 at 07:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A New Jersey judge approved plan voting after a USD 25.00 million claim. For ProPhase Labs stock, second-quarter revenue was USD 1.01 million.

Restructuring and quarterly figures

A bankruptcy claim of USD 25.00 million shaped the latest ProPhase Labs update on October 13, 2026.
ProPhase Labs reported a net loss of USD 3.05 million for the second quarter of 2026 versus USD 5.18 million in the first quarter.
Three ProPhase entities agreed to a tentative USD 900,000 settlement on July 14, 2026.
The next earnings report is listed for November 5, 2026.

PRPH, US74345W2070, Illustration mit AI erstellt.

ProPhase Labs (ISIN US74345W2070) faces a USD 25.00 million claim tied to its bankrupt COVID-19 testing arm after a New Jersey judge approved the disclosure statement for plan voting on October 13, 2026. The immediate meaning for ProPhase Labs stock is a sharper restructuring overhang alongside the company's broader genomics and consumer-health strategy.

Bankruptcy timeline has three markers

On July 14, 2026, three ProPhase Labs entities reached a tentative USD 900,000 settlement with a creditor that had sought to dismiss their Chapter 11 cases or convert them to Chapter 7, according to Law360.

On September 15, 2026, the same court delayed a disclosure-statement hearing by two weeks while the plan accounted for whistleblower litigation, Law360 reported. On October 13, 2026, the claim was set at USD 25.00 million and the disclosure statement received interim approval, according to Law360.

What does the claim mean for revenue?

The court process matters because it competes with ProPhase Labs' operating reset. The investor-relations page identifies the quarter ended June 30, 2026, as the latest financial-results period and describes the company as a biotech, genomics and consumer-products business, according to ProPhase Labs.

For the second quarter of 2026, ProPhase Labs reported a net loss of USD 3.05 million, compared with a USD 5.18 million net loss in the first quarter, according to TradingView. That improvement in the reported loss does not remove the legal uncertainty surrounding the testing subsidiaries, but it gives the restructuring process a concrete financial backdrop.

Next report is listed for November

TradingView lists November 5, 2026, as the next earnings-report date for ProPhase Labs. The date places the next operating update after the October bankruptcy-plan development and could put renewed attention on revenue, cash use and the company's remaining healthcare businesses.